Back
Neurocrine Biosciences Inc (NBIX)
BiotechnologyNBIX · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$142.40
+0.81%Weekly undervalued picks (like NBIX)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$4.67
ROE
22.5%
Gross margin
64.4%
Debt/Equity
0.14x
Revenue growth
42.2%
Neurocrine Biosciences Inc — company intelligence
Earnings surprises
Q2 2026$1.39 vs $1.37 est+1.5%
Q1 2026$1.91 vs $1.20 est+59.5%
Q4 2025$1.91 vs $1.20 est+59.5%
Q3 2025$2.04 vs $1.62 est+26.1%
Analyst consensus · 36 analysts
31 Buy5 Hold0 Sell
Updated Oct 8, 2026
Insider activity · 90 days
11 buys15 sellsnet +19,783 shares
ABERNETHY MATTSell 2,311 · Sep 14, 2026
Boyer David W.Sell 826 · Sep 14, 2026
ABERNETHY MATTSell 2,709 · Sep 11, 2026
Recent SEC filings
8-K — Material event reportSep 28, 2026
4 — Insider transaction reportSep 15, 2026
4 — Insider transaction reportSep 15, 2026
Latest news
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183 — Benzinga · 4w ago
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript — SeekingAlpha · Sep 10, 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript — SeekingAlpha · Sep 9, 2026
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says — Yahoo · Sep 8, 2026
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target — Benzinga · Sep 8, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like NBIX)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.